Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BrightPath Biotherapeutics CoTSE:4594 35 PB Ratio is 4.04 as of Aug. 25, 2026, which is 10% above its 10-year median of 3.66. GuruFocus rates TSE:4594 with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,212 Biotechnology companies, BrightPath Biotherapeutics Co ranks worse than 52.97% on this metric.
BrightPath Biotherapeutics Co Ltd stock PB Ratio (=4.04) is close to 1-year low of 3.69.
The historical rank and industry rank for BrightPath Biotherapeutics Co's PB Ratio or its related term are showing as below:
TSE:4594'
s PB Ratio Range Over the Past 10 Years
Min: 1.3 Med: 3.66 Max: 7.97
Current: 4.04
During the past 12 years, BrightPath Biotherapeutics Co's highest PB Ratio was 7.97. The lowest was 1.30. And the median was 3.66.
TSE:4594's PB Ratio is ranked worse than 52.97% of 1212
companies
in the Biotechnology industry
Industry Median: 2.955
vs TSE:4594: 4.04
During the past 12 months, BrightPath Biotherapeutics Co's average Book Value Per Share Growth Rate was 66.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -29.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -23.60% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of BrightPath Biotherapeutics Co was 60.10% per year. The lowest was -41.60% per year. And the median was -25.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BrightPath Biotherapeutics Co PB Ratio Related Terms
BrightPath Biotherapeutics Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's PB Ratio falls into.
BrightPath Biotherapeutics Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BrightPath Biotherapeutics Co (TSE:4594) has a PB Ratio of 4.04 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BrightPath Biotherapeutics Co and its competitors. This is 10% above median its historical median of 3.66. Over the past decade, BrightPath Biotherapeutics Co's PB Ratio has ranged from 1.30 to 7.97. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #642 out of 1212 companies in the Biotechnology industry, placing it in the top 53%.
Is BrightPath Biotherapeutics Co's PB Ratio too high?
BrightPath Biotherapeutics Co's current PB Ratio of 4.04 is 10% above median its 10-year median of 3.66. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 7.97. The Biotechnology industry median PB Ratio is 2.96. BrightPath Biotherapeutics Co's value of 4.04 is 36.7% above this industry median. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #642 out of 1212 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #642 out of 1212 companies for PB Ratio. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median PB Ratio is 2.96. BrightPath Biotherapeutics Co's value of 4.04 is 36.7% above this benchmark. Historically, BrightPath Biotherapeutics Co's own PB Ratio has ranged from 1.30 to 7.97 over the past decade. While the company's 10-year median is 3.66 vs. the industry median of 2.96, BrightPath Biotherapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.96, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrightPath Biotherapeutics Co's current PB Ratio of 4.04 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current PB Ratio is 4.04, which is 10% above median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current PB Ratio of 4.04. The current PB Ratio is 4.04, which is 10% above median its 10-year median of 3.66 and 36.7% above the Biotechnology industry median of 2.96. BrightPath Biotherapeutics Co's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current PB Ratio is 4.04 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
35GF Score
Get the complete analysis for TSE:4594
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
